Table 3.

Discontinuations of treatment in arthritis because of lack of efficacy or adverse events

			Lack-of-efficacy discontinuations			Adverse-event discontinuations
Duration (weeks)	Treatment	Dose (mg/day)	Number of events	Total number	Discontinuations, % (95% CI)	Number of events	Total number	Discontinuations, % (95% CI)
2–6	Placebo		339	1,925	17.6 (15.8–19.4)	97	1,925	5.0 (4.0–6.0)
	Celecoxib	<100	42	253	16.6 (12.1–21.1)	8	253	3.2 (1.0–5.4)
	Celecoxib	100	No data			No data
	Celecoxib	200	203	4,190	4.8 (4.2–5.4)	223	4,190	5.3 (4.7–5.9)
	Celecoxib	400	12	155	7.7 (3.6–11.8)	5	155	3.2 (0.5–5.9)
	Celecoxib	800	15	180	8.3 (4.2–12.4)	14	180	7.8 (3.9–11.7)
	Paracetamol	4,000	55	502	11.0 (8.3–13.7)	27	502	5.4 (3.4–7.4)
	Rofecoxib	25	19	1,191	1.6 (0.8–2.4)	77	1,191	6.5 (5.1–7.9)
	Naproxen	1,000	5	395	1.3 (0.1–2.5)	31	395	7.8 (5.3–10.3)
	Diclofenac	100/150	13	540	2.4 (1.0–3.8)	51	540	9.4 (6.9–11.9)
12	Placebo		521	1,135	45.9 (43.0–48.8)	70	1,135	6.2 (4.8–7.6)
	Celecoxib	100	145	692	21 (18.1–23.9)	52	692	7.5 (5.5–9.5)
	Celecoxib	200	571	6,094	9.4 (8.6–10.2)	488	6,094	8.0 (7.4–8.6)
	Celecoxib	400	492	6,166	8.0 (7.4–8.6)	590	6,166	9.6 (8.8–10.4)
	Celecoxib	800	128	435	29.4 (25.1–33.7)	28	435	6.4 (4.0–8.8)
	Paracetamol	4,000	No data			No data
	Rofecoxib	25	1	132	0.8 (0.0–2.4)	13	132	9.8 (4.7–14.9)
	Naproxen	1,000	374	2,399	15.6 (14.2–17.0)	316	2,399	13.2 (11.8–14.6)
	Diclofenac	100/150	120	4,311	2.8 (2.2–3.4)	338	4,311	7.8 (7.0–8.6)
	Ibuprofen	2,400	14	345	4.1 (1.9–6.3)	37	345	10.7 (7.4–14)
24+	Placebo		No data			No data
	Celecoxib	100	No data			No data
	Celecoxib	200	No data			No data
	Celecoxib	400	26	326	8.0 (5.1–10.9)	34	326	10.4 (7.1–13.7)
	Celecoxib	800	691	3,987	17.3 (16.1–18.5)	892	3,987	22.4 (21–23.8)
	Paracetamol	4,000	No data			No data
	Rofecoxib	25	No data			No data
	Naproxen	1,000	No data			No data
	Diclofenac	100/150	331	2,325	14.2 (12.8–15.6)	593	2,325	25.5 (23.7–27.3)
	Ibuprofen	2,400	456	1,985	23.0 (21.2–24.8)	456	1,985	23.0 (21.2–24.8)

CI, confidence interval.